Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Depression and bipolar disorder are associated with reduced neural plasticity and deficits in memory, attention and executive function. Drug treatments for these affective disorders have insufficient clinical effects in a large group and fail to reverse cognitive deficits. There is thus a need for more effective treatments which aid cognitive function. Erythropoietin (Epo) is involved in neuroplasticity and is a candidate for future treatment of affective disorders. The investigators have demonstrated that a single dose of Epo improves cognitive function and reduces neurocognitive processing of negative emotional information in healthy and depressed individuals similar to effects seen with conventional antidepressants. The current study adds to the previous findings by investigating whether repeated Epo administration has antidepressant effects in patients with treatment resistant depression and reverses cognitive impairments in these patients and in patients with bipolar disorder in remission. METHODS/DESIGN: The trial has a double-blind, placebo-controlled, parallel-group design. 40 patients with treatment-resistant major depression and 40 patients with bipolar disorder in remission are recruited and randomised to receive weekly infusions of Epo (Eprex; 40,000 IU) or saline (NaCl 0.9%) for 8 weeks. Randomisation is stratified for age and gender. The primary outcome parameters for the two studies are: depression severity measured with the Hamilton Depression Rating Scale 17 items (HDRS-17) 1 in study 1 and, in study 2, verbal memory measured with the Rey Auditory Verbal Learning Test (RAVLT) 23. With inclusion of 40 patients in each study we obtain 86% power to detect clinically relevant differences between intervention and placebo groups on these primary outcomes. TRIAL REGISTRATION: The trial is approved by the Local Ethics Committee: H-C-2008-092, Danish Medicines Agency: 2612-4020, EudraCT: 2008-04857-14, Danish Data Agency: 2008-41-2711 and ClinicalTrials.gov: NCT 00916552.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SCAN: Schedules fonr Clinical Assessment in Neuropsychiatry
Wing, J. K. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810180089012 · Cited by 2,517 · cited 2×
“Patients will be screened with Schedules for Clinical Assessment in Neuropsychiatry (SCAN) [44] to confirm diagnosis.”
MethodNew approaches to antidepressant drug discovery: beyond monoamines
Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589 · cited 1×
“Converging evidence suggests that neural atrophy and reduced neuroplasticity are involved in depression and bipolar disorder, while restoration of synaptic plasticity may be an important mechanism of chronic antidepressant and mood stabilising drug treatment [12-14].”
BackgroundDiagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380 · cited 1×
“For treatmentresistant depression, defined as lack of effect of medication from minimum 2 different classes of antidepressants given in sufficient doses over sufficient time [54,55], there is no scientific evidence for effect of additional pharmacological treatment.”
BackgroundSheline, Y. I., Barch, D. M., Donnelly, J. M., Ollinger, J. M., Snyder, A. Z., & Mintun, M. A. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01263-x · Cited by 1,191 · cited 2×
“Such actions contrast with heightened recognition and neural responses to threatening information in depression [31,32] and may be an important mechanism of antidepressant drug treatment.”
BackgroundHariri, A. R., Goldberg, T. E., Mattay, V. S., Kolachana, B. S., Callicott, J. H., Egan, M. F., & Weinberger, D. R. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-17-06690.2003 · Cited by 1,045 · cited 4×
“Tests used for fMRI scanning are an Nback working memory task, a picture encoding task modified from Hariri et al [38], an emotional face processing task using fearful and happy Nimstim picture stimuli http://www.”
BackgroundMethodInfluentialDEFINITION AND EPIDEMIOLOGY OF TREATMENT-RESISTANT DEPRESSION
Fava, M., & Davidson, K. G. (1996) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70283-5 · Cited by 797
Recombinant Human Erythropoietin in the Treatment of Acute Ischemic Stroke
Ehrenreich, H., Weissenborn, K., Prange, H., Schneider, D., Weimar, C., Wartenberg, K., Schellinger, P. D., Bohn, M., Becker, H., Wegrzyn, M., et al. (2009) · Stroke · doi:10.1161/strokeaha.109.564872 · Cited by 605
Self-citationHarmer, C. J., Shelley, N. C., Cowen, P. J., & Goodwin, G. M. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.7.1256 · Cited by 554
Self-citationEmerging biological roles for erythropoietin in the nervous system
Brines, M., & Cerami, A. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1687 · Cited by 523
Effect of Acute Antidepressant Administration on Negative Affective Bias in Depressed Patients
Harmer, C. J., O’Sullivan, U., Favaron, E., Massey-Chase, R., Ayres, R., Reinecke, A., Goodwin, G. M., & Cowen, P. J. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09020149 · Cited by 485
Self-citation
Cited by
Diaz-Arrastia, R., Kochanek, P. M., Bergold, P., Kenney, K., Marx, C. E., Grimes, C. J. B., Loh, L. Y., Adam, L. G. E., Oskvig, D., Curley, K. C., et al. (2014) · Journal of Neurotrauma · doi:10.1089/neu.2013.3019 · Cited by 262
Miskowiak, K. W., Vinberg, M., Christensen, E. M., Bukh, J. D., Harmer, C. J., Ehrenreich, H., & Kessing, L. V. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2013.335 · Cited by 104
“The EPO-associated memory improvement was twice the size of our a priori estimation of a clinically relevant change (Miskowiak et al, 2010).”
BackgroundMethodInfluentialSelf-citationDemant, K. M., Vinberg, M., Kessing, L. V., & Miskowiak, K. W. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.05.022 · Cited by 91
Self-citationØstergaard, S. D., Bech, P., & Miskowiak, K. W. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.10.047 · Cited by 55
Self-citation
Metadata
- Authors
- Miskowiak, K. W., Vinberg, M., Harmer, C. J., Ehrenreich, H., Knudsen, G. M., Macoveanu, J., Hansen, A. R., Paulson, O. B., Siebner, H. R., & Kessing, L. V.
- Venue
- Trials
- Published
- 2010-10-13
- Volume
- 11
- Issue
- 1
- Pages
- 97-97
- ISSN
- 1745-6215 (ISSN-L)
- OpenAlex
- W2127858610
- Cited by
- 51
- References
- 14
- FWCI
- 3.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder. https://app.cochat.ai/papers/10.1186/1745-6215-11-97
- The paper
- Miskowiak, K. W., Vinberg, M., Harmer, C. J., Ehrenreich, H., Knudsen, G. M., Macoveanu, J., Hansen, A. R., Paulson, O. B., Siebner, H. R., & Kessing, L. V. (2010). Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder. Trials. https://doi.org/10.1186/1745-6215-11-97
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.